CSPC Pharmaceutical Holding Group Co., Ltd., a famous trademark and listed company in Hebei Province, is a pharmaceutical enterprise specializing in the development, production and sales of pharmaceuticals and related products, integrating APIs/patent medicines/innovative drugs/antineoplastic drugs/pharmaceutical commerce/big health business
CSPC Pharmaceutical Holding Group Co., Ltd. has total assets of 24 billion yuan and 19,000 employees. Listed companies in Hong Kong (01093.HK) HK) has a market capitalization of 40 billion Hong Kong dollars, is one of the well-known listed pharmaceutical companies in Hong Kong, and is also a constituent stock of Hong Kong's Hang Seng Red Chip Index.
CSPC Pharmaceutical Group has six business segments: APIs, proprietary medicines, innovative drugs, antineoplastic drugs, pharmaceutical business and general health, mainly engaged in the development, production and sales of pharmaceuticals and related products, including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system drugs, anti-tumor drugs and Chinese patent medicines. CSPC Pharmaceutical Group has more than 30 subsidiaries such as Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Yinhu Pharmaceutical, etc., which are located in Hebei, Kyrgyzstan, Shanxi, Liaoning, Shandong, Jiangsu and Hong Kong, among which Hong Kong CSPC Pharmaceutical Group Co., Ltd., a holding subsidiary located in Hong Kong, is one of the earliest overseas listed companies in China's pharmaceutical industry, one of the largest pharmaceutical listed companies in Hong Kong, and is also one of the constituent stocks of Hong Kong's Hang Seng Red Chip Index.
CSPC Pharmaceutical Group has been recognized as a "National Innovative Enterprise" by the Ministry of Science and Technology of the People's Republic of China and other three ministries and commissions, and its new drug R&D strength ranks among the top pharmaceutical companies in China. Relying on the company's postdoctoral research station, the national enterprise technology center, the "863 Plan" high-tech industrialization base, the State Key Laboratory of Pharmaceutical Preparation and Drug Release Technology and the National Chiral Drug Center, there are currently 180 new drug projects under development in CSPC Pharmaceutical Group, including 25 national first-class new drugs, involving seven major fields such as cardiovascular and cerebrovascular, psychiatric nerve, endocrine, and anti-tumor. The group has successfully marketed the national first-class new drug with independent intellectual property rights, "Enbipu", which is the world's leading drug in the field of stroke treatment, and is the third national first-class new drug with independent intellectual property rights in China, and is protected by patents in 86 countries around the world. At present, the company has signed a patent right transfer agreement with two well-known companies in the United States and South Korea in the European, American and Korean markets, creating a precedent for Chinese pharmaceutical companies to transfer drug intellectual property rights to the world's most developed countries, and winning honor for the country and the nation.
CSPC Pharmaceutical Group has established a complete three-level quality management system, all drugs have passed GMP certification, and all subsidiaries have passed ISO9000, OHSAS18000 and ISO14001 certifications, and the pass rate of product market inspection has always maintained 100%. At present, the group has obtained a total of 16 CEP certificates and 33 DMF registration numbers, and 21 products have successfully passed the on-site inspection of the US FDA, which indicates that the products of CSPC Pharmaceutical Group can be taken to the foreign high-end market to participate in the competition, and the solid preparations can be directly placed on the pharmacies and counters in the United States, which also marks that the drug quality of CSPC Pharmaceutical Group has been connected with the international advanced level.
In terms of fulfilling its social responsibilities, CSPC Pharmaceutical Group has always been at the forefront and has always enthusiastically supported social welfare undertakings, including SARS, Indonesia tsunami, Wenchuan earthquake, Yushu earthquake, medical treatment for seriously ill children, volunteer services, condolences to old areas and other activities. CSPC Pharmaceutical Group has continuously given back to the society with practical things, and has invested more than 100 million yuan in public welfare undertakings since its establishment.
